Darwin Biosciences
Developer of a point-of-care, saliva-based diagnostic platform designed to detect acute-phase infections via an immune-signature biomarker panel and on-device nucleic acid amplification. The platform is described as self-contained and field-deployable, intended for early detection (including sepsis) and for use without centralized laboratories or external power. Founded March 2020, the company transitioned quickly into COVID-19 testing and reports prior operational use and external funding.
Industries
Nr. of Employees
small (1-50)
Products
Point-of-care saliva-based diagnostic platform
A self-contained diagnostic device that uses saliva sampling, on-device sample processing, thermal control, and RNA amplification together with an immune-signature biomarker panel to detect acute-phase infections and support direct nucleic acid detection.
Point-of-care saliva-based diagnostic platform
A self-contained diagnostic device that uses saliva sampling, on-device sample processing, thermal control, and RNA amplification together with an immune-signature biomarker panel to detect acute-phase infections and support direct nucleic acid detection.
Services
Collaborative development and licensing of the diagnostic platform to enable others to build point-of-care molecular diagnostics for human and animal health.
Collaborative development and licensing of the diagnostic platform to enable others to build point-of-care molecular diagnostics for human and animal health.
Expertise Areas
- Point-of-care diagnostics
- Molecular diagnostics (nucleic acid amplification)
- Saliva-based diagnostic sampling
- Immune-signature biomarker development
Key Technologies
- Saliva sample collection
- On-device sample processing
- On-device thermal control/heater activation
- RNA amplification (nucleic acid amplification)
News & Updates
Company founded in March 2020; initial pivot into COVID-19 diagnostic testing.
Reported that the saliva-based solution was used thousands of times and was comparable to other COVID-19 tests.
Reported $17 million of investment supporting development of the diagnostic device.
Company founded in March 2020; initial pivot into COVID-19 diagnostic testing.
Reported that the saliva-based solution was used thousands of times and was comparable to other COVID-19 tests.
Reported $17 million of investment supporting development of the diagnostic device.